Gilead's recent acquisitions are evaluated, highlighting the good, bad, and ugly of the company's BD strategy. The Pharmasset deal was a successful move for Gilead, but subsequent deals have been ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2023 and reaffirmed its 2024 financial guidance (5) provided on December 13, 2023. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results